Nicholas Basta, Editor Emeritus

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Vendors are growing, and product and service offerings are expanding.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.

The provider’s partnership with AI innovator Odaia offers deeper, broader insights to HCP activity.

Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.

Company's annual Commercial Summit updates Veeva Vault CRM status, along with AI partnerships.

Although time has welcomed novel advances in the space, new challenges pertaining to data and the physical technology, along with visibility and sustainability, are emerging.

While vendors fill in gaps in products and services for the supply chain, the action moves toward new cloud-based visibility systems.

Companies' emphasis on delivering pharmaceuticals is evolving into a collaboration focused on healthcare outcomes.

Buyout gives Advanco a bigger US footprint.

The latest IT offerings for sales force automation—including new AI tools—promise a more effective pharma sales process.

A ‘next generation’ CRM platform will gradually leave the Salesforce.com platform behind.

“Deep learning” IT tools were used to calculate sales volumes and drug class.

As a November deadline looms for industry compliance with an interoperable system for product tracing, there is more urgency in the US pharma supply chain.

The Pulse online service will provide free resources to enable pharmacy to meet drug traceability rules.

Post-pandemic conditions are improving for the temperature-controlled market, but, meanwhile, the technical demands are rising.

The pandemic, which stressed all participants in the pharma cold chain, has not stopped innovation in industry practices, as exploration of the main drivers shows

Companies hope to combine their cryogenic expertise with dedicated packaging and supply chain services

The clock is ticking on a massive effort to bring interoperable, electronic tracking of pharma shipments in the US

Biopharma sponsorship of patient-support programs and treatments for rare diseases is growing, but gaps remain

In a civil action, Gilead alleges an extensive, transnational counterfeiting ring of HIV and other drugs

Building a data-sharing system for the US Drug Supply Chain Security Act (DSCSA) is two years from a mandated completion—will industry be ready?

A dramatic shift to e-sampling has been the effective counter to the reduced number of rep visits to physicians’ offices

State and regional economic-development authorities compete fiercely for siting new pharma enterprises, and holding onto the ones they have. But pharma’s stupendous growth in investment is giving all regions a boost

Bypassed a decade ago for traceability applications, radio-frequency identification is making a comeback in hospital pharmacies

At best, 25 million doses might be available by year-end, sufficient for half that many Americans

Pillpack continues its drugs-for-the-day packaging, while parent Amazon works with Express Scripts on drug reimbursement

FDA postpones compliance deadlines to 2023 while issuing new guidance on drug importation